+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SYMBIOTEC

Symbiotec Pharmalab Share Price

₹1,080.10 -53.35 (-4.71%)

15 Sep, 2026 3:58 PM (IST)

Symbiotec Pharmalab live price: ₹1,080.10. It opened at ₹1,134 vs previous close ₹1,133; intraday high/low: ₹1,175/₹1,070.

Symbiotec Pharmalab Performance

  • Today's Low
  • ₹1,070
  • Today's High
  • ₹1,175
  • 52 Week Low
  • ₹934
  • 52 Week High
  • ₹1,194
  • Open Price₹1,134
  • Previous Close₹1,133
  • Volume1,446,184
  • 50 DMA-
  • 100 DMA-
  • 200 DMA-

Symbiotec Pharmalab Chart

Investment Returns

  • Over 1 Month + 9.32%
  • Over 3 Month + 9.32%
  • Over 6 Month + 9.32%
  • Over 1 Year + 9.32%

Smart Investing Starts Here Start SIP with Symbiotec Pharmalab for Steady Growth!

Invest Now

Symbiotec Pharmalab Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 6,940
  • P/B Ratio
  • 6
  • Average True Range
  • -
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • -
  • MFI
  • -

Latest Stock News Updates

Symbiotec Pharmalab Ltd - 544889 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 11, 2026 for Anil Satwani, Sushil Satwani, Kashish Satwani, Satwani Holdings LLP, Kashish and Anil Satwani Family Trust, Arjun Anil Satwani Family Trust & Krishna Anil Satwani Family Trust

Symbiotec Pharmalab Ltd - 544889 - Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of Symbiotec Pharmalab Limited ('The Company') To Be Held On September 21, 2026

Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2026 ,inter alia, to consider and approve To consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026, along with Limited Review Report.

Symbiotec Pharmalab Ltd - 544889 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Beacon Trusteeship Ltd

Symbiotec Pharmalab Financials

Symbiotec Pharmalab Technicals

EMA & SMA

Current Price
₹1,080.10
-53.35 (-4.71%)
pointer
  • Bearish Moving Average 4
  • Bullish Moving Average 0
  • 20 Day
  • -
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1108.33 Pivot Speed
  • R3 1,251.50
  • R2 1,213.20
  • R1 1,146.60
  • S1 1,041.80
  • S2 1,003.50
  • S3 937.00

Symbiotec Pharmalab Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-09-21 Quarterly Results

Symbiotec Pharmalab Shareholding Pattern

33.28%
21.97%
21.08%
18.12%
5.54%

About Symbiotec Pharmalab

Symbiotec Pharmalab are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. View More
  • NSE Symbol
  • SYMBIOTEC
  • BSE Symbol
  • 544889
  • ISIN
  • INE899I01028

Similar Stocks to Symbiotec Pharmalab

Symbiotec Pharmalab FAQs

Symbiotec Pharmalab share price is ₹1,080 As on 15 September, 2026 | 22:11

The Market Cap of Symbiotec Pharmalab is ₹6940.3 Cr As on 15 September, 2026 | 22:11

The P/E ratio of Symbiotec Pharmalab is As on 15 September, 2026 | 22:11

The PB ratio of Symbiotec Pharmalab is 6 As on 15 September, 2026 | 22:11

The 52 week High & Low of Symbiotec Pharmalab is ₹1193.7/₹934.2 respectively As on 15 September, 2026 | 22:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23